Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. SILO
stocks logo

SILO

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Valuation Metrics

The current forward P/E ratio for Silo Pharma Inc (SILO.O) is -0.65, compared to its 5-year average forward P/E of -1.21. For a more detailed relative valuation and DCF analysis to assess Silo Pharma Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-1.21
Current PE
-0.65
Overvalued PE
-0.02
Undervalued PE
-2.41

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
46.73
Current PS
0.00
Overvalued PS
89.10
Undervalued PS
4.35
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

SILO News & Events

Events Timeline

(ET)
2025-11-17
08:06:29
Silo Pharma collaborates with Allucent for upcoming FDA IND submission for SPC-15
select
2025-10-29 (ET)
2025-10-29
08:29:04
Silo Pharma Chooses AlphaLedger's T12 Fund for Tokenized Real-World Asset Investments
select
2025-10-23 (ET)
2025-10-23
08:48:56
Silo Pharma shares progress on SPC-15 development and digital asset initiative.
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.0
11-17Newsfilter
Silo Pharma Collaborates with Allucent to Assist in Upcoming FDA Investigational New Drug Application for SPC-15 as a PTSD Treatment

  • Silo Pharma's IND Submission: Silo Pharma has partnered with Allucent to prepare for the submission of its investigational new drug application (IND) to the FDA for a Phase 1 clinical trial of its intranasal treatment SPC-15 for PTSD, expected in 2026.

  • Clinical Development Plans: The company aims to utilize Allucent's expertise to ensure the IND meets FDA standards, focusing on dose-ranging studies to evaluate the pharmacokinetics and safety of SPC-15.

  • Research and Development Focus: Silo Pharma is dedicated to developing therapies for underserved conditions, including PTSD, chronic pain, and CNS diseases, with a portfolio that includes multiple innovative programs.

  • Allucent's Role: Allucent is a global clinical research organization that provides comprehensive drug development solutions, leveraging over 30 years of experience to assist biopharma clients in navigating the complexities of bringing new therapies to market.

[object Object]
Preview
9.0
10-23Newsfilter
Silo Pharma Provides Update on Progress in PTSD Drug Development and Launches New Digital Assets Treasury Initiative

  • Biopharmaceutical Developments: Silo Pharma is preparing to submit an investigational new drug (IND) application for its lead candidate SPC-15, an intranasal treatment for PTSD, following positive safety study results and completion of necessary toxicology studies.

  • Digital Assets Strategy: The company has launched a digital assets treasury strategy, making initial cryptocurrency purchases and appointing a lead crypto strategy advisor to manage its portfolio and enhance compliance.

  • Future Catalysts: Key upcoming milestones include data from the IND-enabling study expected in 2026, FDA discussions to finalize IND submission requirements, and plans to expand therapeutic indications for SPC-15.

  • Company Overview: Silo Pharma focuses on developing treatments for underserved conditions, including PTSD and chronic pain, while also engaging in cryptocurrency investments to strengthen its capital resources.

[object Object]
Preview
8.5
10-02Newsfilter
Silo Pharma Completes $2.5 Million Registered Direct Offering at Market Price in Compliance with Nasdaq Regulations

  • Silo Pharma's Offering: Silo Pharma, Inc. has closed a registered direct offering of 2,857,143 shares of common stock at $0.875 per share, raising approximately $2.5 million for working capital and corporate purposes.

  • Warrants Issued: In a concurrent private placement, the company issued unregistered warrants to purchase an equal number of shares at an exercise price of $0.75, which are immediately exercisable and will expire in five years.

  • Regulatory Compliance: The common stock was offered under an effective registration statement with the SEC, while the unregistered warrants were offered in a private placement and are not registered under the Securities Act.

  • Company Focus: Silo Pharma is a developmental-stage biopharmaceutical company targeting underserved conditions such as PTSD and chronic pain, with research collaborations with leading universities and laboratories.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Silo Pharma Inc (SILO) stock price today?

The current price of SILO is 0.4515 USD — it has decreased -0.88 % in the last trading day.

arrow icon

What is Silo Pharma Inc (SILO)'s business?

Silo Pharma, Inc. is a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company. The Company’s therapeutic focus is on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. The Company’s portfolio includes programs, such as for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer’s disease and multiple sclerosis. Its lead product candidate, SPC-15, is designed as a novel serotonin 4 (5-HT4) receptor agonist that utilizes biomarkers for treatment of stress-induced psychiatric disorders such as PTSD and anxiety disorders. SPC-14 targets glutamate receptor NDMAR and serotonin 5-HT4 to address cognitive and neuropsychiatric symptoms in Alzheimer’s disease. SPU-16 is a candidate targeting central nervous system (CNS) disorders, with an initial indication for multiple sclerosis.

arrow icon

What is the price predicton of SILO Stock?

Wall Street analysts forecast SILO stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for SILO is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Silo Pharma Inc (SILO)'s revenue for the last quarter?

Silo Pharma Inc revenue for the last quarter amounts to 18.03K USD, decreased 0.00 % YoY.

arrow icon

What is Silo Pharma Inc (SILO)'s earnings per share (EPS) for the last quarter?

Silo Pharma Inc. EPS for the last quarter amounts to -0.12 USD, decreased -45.45 % YoY.

arrow icon

What changes have occurred in the market's expectations for Silo Pharma Inc (SILO)'s fundamentals?

The market is revising No Change the revenue expectations for SILO for , with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -26.04%.
arrow icon

How many employees does Silo Pharma Inc (SILO). have?

Silo Pharma Inc (SILO) has 3 emplpoyees as of December 05 2025.

arrow icon

What is Silo Pharma Inc (SILO) market cap?

Today SILO has the market capitalization of 6.01M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free